This company has been acquired
Societal CDMO (SCTL) Stock Overview
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SCTL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Societal CDMO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$1.28 |
| 52 Week Low | US$0.26 |
| Beta | 1.52 |
| 1 Month Change | 1.85% |
| 3 Month Change | 181.33% |
| 1 Year Change | 4.76% |
| 3 Year Change | -65.52% |
| 5 Year Change | -86.89% |
| Change since IPO | -86.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| SCTL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | 1.2% |
| 1Y | 4.8% | 36.2% | 27.0% |
Return vs Industry: SCTL underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: SCTL underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| SCTL volatility | |
|---|---|
| SCTL Average Weekly Movement | 39.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SCTL's share price has been volatile over the past 3 months.
Volatility Over Time: SCTL's weekly volatility has increased from 23% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 258 | J. Enloe | www.societalcdmo.com |
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms.
Societal CDMO, Inc. Fundamentals Summary
| SCTL fundamental statistics | |
|---|---|
| Market cap | US$116.26m |
| Earnings (TTM) | -US$13.27m |
| Revenue (TTM) | US$94.64m |
Is SCTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCTL income statement (TTM) | |
|---|---|
| Revenue | US$94.64m |
| Cost of Revenue | US$76.50m |
| Gross Profit | US$18.14m |
| Other Expenses | US$31.41m |
| Earnings | -US$13.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 19.17% |
| Net Profit Margin | -14.03% |
| Debt/Equity Ratio | 63.2% |
How did SCTL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/08 08:03 |
| End of Day Share Price | 2024/04/08 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Societal CDMO, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Patrick Trucchio | Berenberg |
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |